Medullary Thyroid Cancer: A Review
Authors
Abstract:
Thyroid cancer is a malignancy of the thyroid parenchymal cells. There are four main types of thyroid cancer: papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid carcinoma (ATC), and Medullary thyroid carcinoma (MTC). Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor of the thyroid gland derived from parafollicular C-cells that produce calcitonin (CT) and accounts for 5-8% of all thyroid cancers. It is responsible for a disproportionate number of thyroid cancer deaths because of the lack of adjuvant treatment beyond surgery. MTC may occur sporadically or be inherited. Hereditary pattern includes multiple endocrine neoplasia syndrome types 2A and 2B. The majority of MTC cases are sporadic, but a hereditary pattern is present in 20-30% of cases. RET mutations occur in over 90% of hereditary and 40% of sporadic MTC. Total thyroidectomy remains the standard treatment for MTC patients. Early diagnosis and treatment are necessary for a 100% cure rate.
similar resources
RET proto-oncogene mutations in the diagnosis of medullary thyroid cancer: a review article
Medullary thyroid cancer accounts for 5-10% of thyroid carcinomas. RET proto-oncogene mutations occur in all of the hereditary MTCs and about 66% of the sporadic MTCs. So, the detection of the RET mutations is necessary for rapid and proper diagnosis and treatment. This systematic review seeks to find a comprehensive list of RET gene mutations in the diagnosis of medullary thyroid cancer. The ...
full textGenetic and Epigenetic of Medullary Thyroid Cancer
Medullary thyroid carcinoma (MTC) is an infrequent calcitonin-producing neuroendocrine tumor that initiates from the parafollicular C cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we shed light on all the genetic and epigenetic hallmarks of MTC. From the genetic perspective, RET, ...
full text[Medullary thyroid cancer: review of 28 patients].
BACKGROUND Medullary thyroid cancer (MTC) represents approximately 5% of all thyroid cancers. Surgery is the only curative treatment, which includes total thyroidectomy and in most cases, neck dissection. AIM To report our 10-year experience with surgical treatment of MTC. MATERIAL AND METHODS Review of medical records and pathology reports of a university hospital. We retrieved data from 2...
full textCabozantinib for progressive metastatic medullary thyroid cancer: a review
Medullary thyroid cancer is uncommon and patients typically present with advanced disease. Treatment options for patients with progressive, metastatic medullary thyroid cancer had been limited until recently. Tyrosine kinase inhibitors have garnered increasing interest in this subset of patients. The US Food and Drug Administration recently approved cabozantinib, a tyrosine kinase inhibitor, af...
full textTargeted Therapy for Medullary Thyroid Cancer: A Review
Medullary thyroid cancers (MTCs) constitute between 2 and 5% of all thyroid cancers. The 10-year overall survival (OS) rate of patients with localized disease is around 95% while that of patients with regional stage disease is about 75%. Only 20% of patients with distant metastases at diagnosis survive 10 years which is significantly lower than for differentiated thyroid cancers. Cases with reg...
full textMedullary Thyroid Cancer.
BACKGROUND: Medullary thyroid cancer, a tumor of the parafollicular C cells, accounts for approximately 10% of all thyroid malignancies. An estimated 75% of cases are sporadic, and the remaining 25% are familial. METHODS: The author reviews the clinical features and diagnostic tests for this entity, as well as the surgical treatment of recurrent or persistent medullary carcinoma. RESULTS: Spora...
full textMy Resources
Journal title
volume 13 issue 54
pages 60- 65
publication date 2022-03
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023